Summary

FDA approved Isembyld (apitegromab) from Scholar Rock on September 11, 2026. The drug treats spinal muscular atrophy (SMA) in adults and children aged 2 and older. It is the first muscle-targeted therapy for the disease. The list price is about $310,000 per year. Consequently, it enters a market already served by three other approved SMA treatments, each with an established price and track record. Notably, Scholar Rock’s stock had languished for years before strong 2024 trial data reignited investor interest.

Access Impact

A new price layer, not a new category. Isembyld does not replace existing SMA drugs. Instead, it is approved for use alongside SMN2-targeted therapies such as Zolgensma, Spinraza, and Evrysdi. This changes the access question for payers. Specifically, instead of asking whether Isembyld is worth its price alone, payers must ask whether it is worth its price on top of what patients already take. The relevant MARA domain here is Budget Impact, together with Comparator Selection. Notably, analysts project peak sales near $2 billion. That figure signals strong expected uptake, even before payers have tested how they will handle the combined cost.

Comparator Selection

Isembyld’s pivotal trial measured its effect when added to standard care. It was not tested head-to-head against a single existing SMA drug. This is a common design in rare disease trials, where withholding standard treatment from patients is not ethical. However, it also means the trial cannot show whether Isembyld’s benefit differs across the three existing SMN2-targeted options. For payers comparing total treatment cost, this gap matters. It leaves the added value over each existing drug unconfirmed. By contrast, a head-to-head comparison would have given payers a clearer basis for combination-therapy value judgments.

Budget Impact

At $310,000 per year, Isembyld does not stand alone in a patient’s treatment cost. It sits on top of Zolgensma, Spinraza, or Evrysdi, each already priced in the high five or six figures annually. For a health system, the true budget question is the combined annual cost per patient. It is not Isembyld’s price in isolation. As a result, payers will likely apply extra scrutiny to combination-therapy budget models before granting broad access. Furthermore, budget-impact analyses will need to account for the small but real patient population affected by SMA, which limits the ability to spread cost risk across a larger pool.

Evidence Quality

Isembyld’s path to approval was not straightforward. The FDA rejected the drug in September 2025 over manufacturing concerns at a third-party facility. Scholar Rock spent the following year replacing that facility and refiling its application. This history signals a level of regulatory and manufacturing risk worth tracking going forward. Moreover, the approved label carries a new warning for bone fracture risk that was not disclosed in earlier trial reporting. Both points suggest the long-term safety and manufacturing record is still maturing, even as the drug reaches patients. Specifically, analysts flagged the fracture warning as unexpected, since earlier trial disclosures had not mentioned it. Even so, the treatment received a priority review voucher, reflecting the FDA’s view of its value for a serious, rare condition.

Risk Signal

An add-on price, an open safety signal, and no head-to-head data. For a portfolio manager, Isembyld represents a specific kind of market-access risk. It combines strong clinical promise with a cost structure and evidence base that are both still unproven at scale. Peak sales estimates of $2 billion assume broad payer acceptance of combination pricing. That acceptance has not yet been tested in the market. Instead, payers may push back on stacking Isembyld’s cost onto existing SMA regimens. Alternatively, the bone-fracture signal could grow as more patients are exposed to the drug. Therefore, the gap between analyst projections and what payers actually approve is worth watching closely over the next several quarters. What happens to that $2 billion forecast if even one major payer treats Isembyld as optional rather than standard of care?

#MarketAccess #HTA #MARArating #SMA #RareDisease

Explore MARA’s market-access framework: https://mararating.com/market-access-pharma/

See MARA’s full ratings list: https://mararating.com/mara-ratings-list